ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/breast/metastatic/her2-positive/subsequent
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Breast / Breast - Metastatic / HER2-positive / Subsequent
9
trial(s) found.
NCT06625775
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study) (
TBBO10203-101
)
PI3K alpha-RAS breaker
Breast cancer
Colorectal cancer
HER2-negative breast cancer
HER2-positive breast cancer
Non-small cell lung cancer
RAS-mutant colorectal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06435429
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment (
JZP598-303
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
bispecific ERBB2/ERBB2 antibody
HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3149 - Mount Waverley - Waverley Private Hospital - Oncology
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06157892
Advanced
Phase 2
Recruiting
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors (
SGNDV-004
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-low breast cancer
HER2-positive breast cancer
Triple-negative breast cancer
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NA
NA
NCT06018337
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Multi-center, Open-Label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (
DB-1303-O-3002
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
3844 - Traralgon - Latrobe Regional Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05950945
Advanced
Phase 3
Recruiting
A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15) (
DS8201-0001-CIS-MA
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
NSW
2060 - North Sydney - Mater Hospital
VIC
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05872295
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors (
IKS014-01
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT05081609
Advanced
Phase 1 / Phase 2
Recruiting
IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (
IL-Believe
)
TLR7/TLR8 agonist
anti-PD-1 monoclonal antibody
Breast cancer
Cervical cancer
Melanoma
Non-small cell lung cancer
Platinum resistant ovarian cancer
Small-cell lung cancer
Solid tumour
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5065 - Toorak Gardens - Burnside War Memorial Hospital (TERMINATED)
NCT04802759
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (
CO42867
)
AKT inhibitor
Abemaciclib
Atezolizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CDK7 inhibitor
ER degrader
Everolimus
Giredestrant
Inavolisib
Ipatasertib
PI3K alpha inhibitor
Palbociclib
Pertuzumab
Ribociclib
Samuraciclib
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CDK7-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3K alpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,PD-L1-targeting
mTORC1 inhibitor
mTOR inhibitor
oestrogen receptor-targeting therapy
pan-AKT inhibitor
selective estrogen receptor degrader
Breast cancer
ER-positive breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT03424005
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Treatment Combinations In Patients With Metastatic Breast Cancer (
Morpheus-panBC
)
AKT inhibitor
Abemaciclib
Atezolizumab
Bevacizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Capecitabine
Carboplatin
ER degrader
Eribulin
Fulvestrant
Gemcitabine
Inavolisib
Ipatasertib
Ladiratuzumab Vedotin
Letrozole
Nab-paclitaxel
PI3K alpha inhibitor
Ribociclib
Sacituzumab Govitecan
Selicrelumab
Tocilizumab
Trastuzumab Deruxtecan
agnostic antibody,CD40-targeting
anti-CD40 agonistic antibody
anti-ERBB2 antibody-drug conjugate
anti-IL-6 monoclonal antibody
anti-LIV1 antibody-drug conjugate
anti-PD-L1 monoclonal antibody
anti-Trop2 antibody-drug conjugate
anti-VEGF monoclonal antibody
antimetabolite
aromatase inhibitor
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CD40-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,IL-6-targeting
cancer therapy,LIV1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3K alpha-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
endocrine therapy
endocrine therapy,oestrogen axis-targeting
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CD40-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LIV1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGF-targeting
macrocyclic ketone analogue
oestrogen receptor-targeting therapy
pan-AKT inhibitor
platinum-based antineoplastic agent
selective estrogen receptor degrader
taxane
Breast cancer
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (9)
Recruitment Country and State
VIC (9)
WA (6)
NSW (5)
SA (4)
QLD (3)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (3)
Phase 2 (1)
Phase 3 (3)
Trial Type
Advanced (9)
Cancer Therapy Class
ERBB2
100%
CDK4
33%
CDK6
33%
ER
33%
PI3K alpha
33%
oestrogen axis
33%
PD-1/PD-L1
33%
VEGF
22%
AKT
22%
PD-L1
22%
PD-1
11%
TLR7/TLR8
11%
CDK7
11%
mTOR
11%
mTORC1
11%
CD40
11%
IL-6
11%
LIV1
11%
Trop2
11%
Facility
3199 - Frankston - Peninsula Health Frankston Hospital (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
2109 - North Ryde - Macquarie University Hospital (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
6009 - Nedlands - Linear Clinical Research (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3149 - Mount Waverley - Waverley Private Hospital - Oncology (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
NA
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2170 - Liverpool - Liverpool Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2060 - North Sydney - Mater Hospital (1)
3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
4215 - Southport - Tasman Oncology (1)
5065 - Toorak Gardens - Burnside War Memorial Hospital (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
Cancer Type
Breast cancer
Cancer
Solid tumour
Breast adenocarcinoma
Thoracic cancer
Gastrointestinal cancer
HER2-positive breast cancer
HER2-negative breast cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Upper gastrointestinal cancer
Colorectal adenocarcinoma
Colorectal cancer
Lower gastrointestinal cancer
RAS-mutant colorectal cancer
HER2-low breast cancer
Triple-negative breast cancer
Carcinoma
Cervical cancer
Epithelial Ovarian Cancer
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Melanoma
Neuroendocrine carcinoma
Ovarian adenocarcinoma
Ovarian cancer
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Viral-related cancer
ER-positive breast cancer
HR-positive breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy